These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24385535)

  • 1. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM; Garcia DA; Crowther MA
    Blood; 2014 Feb; 123(8):1152-8. PubMed ID: 24385535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
    Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM; Keenan JC; Morton CT; Dries DJ
    Biomed Res Int; 2014; 2014():583794. PubMed ID: 25136597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extended options of anticoagulant treatment in thromboembolism].
    Karetová D; Bultas J
    Vnitr Lek; 2014 Nov; 60(11):977-84. PubMed ID: 25600045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A; Michel MS
    Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A; Lang ES; Douketis J
    Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML; Nash JE; Stabi KL
    J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.